EMA clears GLP-1 diabetes drugs of pancreatitis
The European Medicines Agency�s Committee for Medicinal Products for Human Use has finalised a review of GLP-1-based diabetes therapies and concluded that "presently available data do not confirm recent concerns over an increased risk of pancreatic adverse events with these medicines". This review followed the publication of a study wherein researchers suggested an increased risk of pancreatitis and cellular changes called pancreatic-duct metaplasia appeared in patients with Type-2 Diabetes treated with GLP-1-based therapies.
The CHMP says that the study "had a number of methodological limitations and potential sources of bias, most importantly differences between the studied groups with respect to age, gender, disease duration and treatments, which preclude a meaningful interpretation of the results".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.